Accordingly, blocking TGF-β signaling to prevent myCAF differentiation, targeting SPP1 to disrupt CAF–tumor cell crosstalk, or inhibiting downstream ERK/MAPK signaling can restore sensitivity to ADT. This evidence concerns the gene TGFB1 and neoplasm.